A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

Hashtag, a weekly place for broader context. Saturday Hashtag: #FederalRegulatoryFailure originally appeared on WhoWhatWhy ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma ...

Abdominal obesity is a greater risk factor for psoriasis than total body fat, according to an analysis of imaging data, ...

Deal volume fell by 24 per cent to its lowest level since mid-2020, despite predictions of a surge in activity in the wake of ...

Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.

Driven by self-medication trends, health-conscious consumers, and innovative formulations, the OTC drugs market thrives on the widespread availabilit ...

Neglected tropical diseases (NTDs) are a diverse group of conditions1 that still affect 1 billion people, mainly vulnerable populations in underserved ...

Global Akeega sales will reach $676 million by 2030, while Talzenna and saruparib reach $618 million and $628 million ...

GlaxoSmithKline (GSK – Research Report) received a Hold rating and a $41.00 price target from Berenberg Bank analyst Kerry Holford today. Confident Investing Starts Here: Easily ...